Enzyme Discovery Reduces Alzheimer’s Plaques by 70%

By VirentaNews Staff — May 20, 2026

Alzheimer’s disease affects over 55 million people worldwide, with no cure and limited treatment options—until now. In a landmark study published in Nature, researchers have identified a previously overlooked enzyme, IDOL (Inducible Degrader of the LDL receptor), as a critical driver of amyloid-beta accumulation in the brain. When scientists genetically removed IDOL from human neurons derived from Alzheimer’s patients, they observed up to a 70% reduction in amyloid plaques—the hallmark of the disease—along with improved synaptic function and enhanced cellular resilience. This discovery marks a pivotal shift from merely managing symptoms to potentially halting or even reversing key neurodegenerative processes at the molecular level.

A Hidden Culprit Behind Cognitive Decline

For decades, Alzheimer’s research has focused on amyloid-beta and tau proteins as central players in neurodegeneration. However, therapies targeting these proteins have yielded mixed results, often slowing decline only marginally without stopping disease progression. The breakthrough with IDOL represents a paradigm shift: instead of attacking the end products of neurodegeneration, scientists are now targeting a regulatory switch that controls neuronal vulnerability. IDOL, originally studied for its role in cholesterol metabolism, was unexpectedly found to degrade proteins essential for synaptic integrity and amyloid clearance. Its overactivity appears to weaken the brain’s natural defenses, allowing toxic plaques to accumulate unchecked. With Alzheimer’s cases projected to triple by 2050, this discovery arrives at a critical juncture, offering a novel pathway for intervention that could fundamentally alter treatment strategies.

How IDOL Fuels Alzheimer’s Pathology

The research team, led by neuroscientists at the University of California, San Diego and the Gladstone Institutes, used induced pluripotent stem cells (iPSCs) from Alzheimer’s patients to grow functional human neurons in the lab. By applying CRISPR gene-editing technology, they deactivated the IDOL gene and monitored changes in cellular behavior. The results were striking: not only did amyloid-beta levels drop significantly, but neurons also showed increased expression of LRP1, a receptor critical for clearing amyloid from the brain. Additionally, synapses—the junctions where neurons communicate—became more stable and active. These improvements occurred without altering levels of APP (amyloid precursor protein), suggesting IDOL operates independently of traditional amyloid production pathways. Further experiments in mouse models confirmed that suppressing IDOL boosted cognitive performance in memory and navigation tasks, reinforcing its role as a master regulator of brain resilience.

Mechanisms and Molecular Crossroads

IDOL’s primary function is to tag certain proteins for destruction, a process known as ubiquitination. In the brain, it targets LRP1, which shuttles amyloid-beta out of the brain and across the blood-brain barrier. When IDOL is overactive, LRP1 levels fall, impairing the brain’s ability to detoxify. The study revealed that inflammatory signals—common in aging brains and exacerbated by conditions like diabetes and cardiovascular disease—trigger IDOL upregulation, creating a vicious cycle of accumulation and neuronal stress. This explains, in part, why patients with metabolic disorders face higher Alzheimer’s risk. By blocking IDOL, researchers effectively preserved LRP1, enhancing the brain’s natural clearance mechanisms. Experts liken this approach to reinforcing a city’s sanitation system rather than just cleaning up trash: it strengthens the underlying infrastructure that prevents buildup in the first place.

Implications for Patients and Drug Development

If translated to humans, IDOL inhibition could benefit millions at risk of or living with early-stage Alzheimer’s. Unlike current drugs such as lecanemab, which remove existing plaques but carry risks like brain swelling, targeting IDOL may offer a safer, preventive strategy by enhancing the brain’s intrinsic defenses. Pharmaceutical companies are already exploring small-molecule inhibitors of IDOL, aiming to develop oral medications that cross the blood-brain barrier. The approach might also complement existing immunotherapies, offering a dual-pronged attack: reduce production and boost clearance. Importantly, because IDOL modulation appears to improve synaptic health independently of amyloid, it could also support cognitive function even in non-Alzheimer’s dementias, broadening its therapeutic potential across neurodegenerative conditions.

Expert Perspectives

Dr. Yadong Huang, senior author of the study, stated, “We’ve shifted from cleaning up the mess to strengthening the system that prevents the mess in the first place.” Other experts urge cautious optimism. Dr. Maria Carrillo of the Alzheimer’s Association noted, “While promising, we must ensure that long-term IDOL suppression doesn’t disrupt cholesterol regulation elsewhere in the body.” Some neuroscientists warn that mouse models don’t always predict human outcomes, emphasizing the need for rigorous clinical testing. Still, the convergence of genetic, cellular, and behavioral evidence has galvanized the research community, with many calling this one of the most compelling new targets in a decade.

Looking ahead, the next critical step is developing safe, brain-specific IDOL inhibitors and testing them in human trials. Researchers are also exploring biomarkers to identify patients with high IDOL activity who might benefit most. If successful, this could usher in a new class of neuroprotective drugs—one that doesn’t just slow decline but actively fortifies the aging brain. The question is no longer whether we can intervene, but how soon we can bring this breakthrough from the lab to the clinic.

Source: ScienceDaily